The first official IPA Board Meeting occurred in Rotterdam, The Netherlands on Feb. 18-19, 2002. Future agendas were planned and the following committees were formed. Communications—Kevin O’Donnell, Alan Muir, Marylyn House Patient Organizations—Maryze Schoneveld,...

The International Pompe Association (IPA) board will meet on February 18-19th, 2002. Representatives of scientific/medical teams and Genzyme will attend. The following issues will be discussed: 1. Finalize the universal patient questionnaire to be distributed in the...

October 2001—CAMBRIDGE, Mass.—Genzyme Corporation announced today that it has acquired certain assets of Pharming N.V., the Belgian subsidiary of the Pharming Group currently operating under a court-supervised receivership. These assets include a 70,000 square foot...

Proprietary Glycoprotein Technology Platform Will Advance Lysosomal Storage Disorder Programs Excerpt from August 7, 2001 Press Release Genzyme Corp. and privately held Novazyme Pharmaceuticals Inc. today announced a definitive merger agreement under which Novazyme...

Article on Transgenic Enzyme Replacement Therapy Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT. Department of Pediatrics, Sophia Children’s...

This is an approximate transcript (i.e. from notes, not a tape) of an interview between Novazyme and the International Pompe Association (IPA). The participants were, from Novazyme: John Crowley (CEO), Julie Anne Smith (Senior Director, Patient Advocacy), William...

The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the AGSD-UK (Association for Glycogen Storage Disease-United Kingdom. Kevin O’Donnell interviewed Paul Kaplan, General Manager of the...

Excerpt from Pharming Press Release—March 30, 2001 LEIDEN, the Netherlands, March 30, 2001 - Pharming Group N.V. announced the start of a Phase II-III clinical trial of an enzyme replacement therapy for Pompe’s disease. The trial, under management of the...

Excerpt From Press Release-March 20, 2001 CAMBRIDGE, MA and LEIDEN,the Netherlands—Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., and Pharming Group N.V. (AEX: PHAR and EASDAQ: PHAR) announced the publication March 20 in Genetics in Medicine...

The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the AGSD-UK (Association for Glycogen Storage Disease-United Kingdom. Kevin O’Donnell interviewed Paul Kaplan, General Manager of the...